Your browser doesn't support javascript.
loading
Variation in the Proportion of Adults in Need of Blood Pressure-Lowering Medications by Hypertension Care Guideline in Low- and Middle-Income Countries: A Cross-Sectional Study of 1 037 215 Individuals From 50 Nationally Representative Surveys.
Sudharsanan, Nikkil; Theilmann, Michaela; Kirschbaum, Tabea K; Manne-Goehler, Jennifer; Azadnajafabad, Sina; Bovet, Pascal; Chen, Simiao; Damasceno, Albertino; De Neve, Jan-Walter; Dorobantu, Maria; Ebert, Cara; Farzadfar, Farshad; Gathecha, Gladwell; Gurung, Mongal Singh; Jamshidi, Kosar; Jørgensen, Jutta M A; Labadarios, Demetre; Lemp, Julia; Lunet, Nuno; Mwangi, Joseph K; Moghaddam, Sahar Saeedi; Bahendeka, Silver K; Zhumadilov, Zhaxybay; Bärnighausen, Till; Vollmer, Sebastian; Atun, Rifat; Davies, Justine I; Geldsetzer, Pascal.
Afiliación
  • Sudharsanan N; Heidelberg Institute of Global Health, Heidelberg University, Germany (N.S., M.T., T.K.K., S.C., J.-W.D.N., J.L., T.B.).
  • Theilmann M; Heidelberg Institute of Global Health, Heidelberg University, Germany (N.S., M.T., T.K.K., S.C., J.-W.D.N., J.L., T.B.).
  • Kirschbaum TK; Heidelberg Institute of Global Health, Heidelberg University, Germany (N.S., M.T., T.K.K., S.C., J.-W.D.N., J.L., T.B.).
  • Manne-Goehler J; Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston (J.M.-G.).
  • Azadnajafabad S; Tehran University of Medical Sciences, Iran (S.A., F.F., K.J., S.S.M.).
  • Bovet P; Institute of Social and Preventive Medicine, Bern, Switzerland (P.B.).
  • Chen S; Heidelberg Institute of Global Health, Heidelberg University, Germany (N.S., M.T., T.K.K., S.C., J.-W.D.N., J.L., T.B.).
  • Damasceno A; Faculty of Medicine, Eduardo Mondlane University, Maputo, Mozambique (A.D.).
  • De Neve JW; Heidelberg Institute of Global Health, Heidelberg University, Germany (N.S., M.T., T.K.K., S.C., J.-W.D.N., J.L., T.B.).
  • Dorobantu M; Cardiology Department, Emergency Hospital of Bucharest, Romania (M.D.).
  • Ebert C; RWI-Leibniz Institute for Economic Research, Essen, Germany (C.E.).
  • Farzadfar F; Tehran University of Medical Sciences, Iran (S.A., F.F., K.J., S.S.M.).
  • Gathecha G; Division of Non-Communicable Diseases, Ministry of Health, Nairobi, Kenya (G.G.).
  • Gurung MS; Health Research and Epidemiology Unit, Ministry of Health, Thimphu, Bhutan (M.S.G.).
  • Jamshidi K; Tehran University of Medical Sciences, Iran (S.A., F.F., K.J., S.S.M.).
  • Jørgensen JMA; D-Tree International, Norwell, MA (J.M.A.J.).
  • Labadarios D; Faculty of Medicine and Health Sciences, Stellenbosch University, South Africa (D.L.).
  • Lemp J; Heidelberg Institute of Global Health, Heidelberg University, Germany (N.S., M.T., T.K.K., S.C., J.-W.D.N., J.L., T.B.).
  • Lunet N; Department of Public and Forensic Health Sciences and Medical Education, Faculty of Medicine, University of Porto, Portugal (N.L.).
  • Mwangi JK; Department of Strategic National Public Health Programs, Ministry of Health, Nairobi, Kenya (J.K.M.).
  • Moghaddam SS; Tehran University of Medical Sciences, Iran (S.A., F.F., K.J., S.S.M.).
  • Bahendeka SK; Saint Francis Hospital, Kampala, Uganda (S.K.B.).
  • Zhumadilov Z; National Laboratory Astana, University Medical Centre, Nazarbayev University, Kazakhstan (Z.Z.).
  • Bärnighausen T; Heidelberg Institute of Global Health, Heidelberg University, Germany (N.S., M.T., T.K.K., S.C., J.-W.D.N., J.L., T.B.).
  • Vollmer S; Department of Economics and Centre for Modern Indian Studies, University of Göttingen, Germany (S.V.).
  • Atun R; Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA (R.A.).
  • Davies JI; Institute of Applied Health Research, University of Birmingham, United Kingdom (J.I.D.).
  • Geldsetzer P; Division of Primary Care and Population Health, Department of Medicine, Stanford University, CA (P.G.).
Circulation ; 143(10): 991-1001, 2021 03 09.
Article en En | MEDLINE | ID: mdl-33554610
ABSTRACT

BACKGROUND:

Current hypertension guidelines vary substantially in their definition of who should be offered blood pressure-lowering medications. Understanding the effect of guideline choice on the proportion of adults who require treatment is crucial for planning and scaling up hypertension care in low- and middle-income countries.

METHODS:

We extracted cross-sectional data on age, sex, blood pressure, hypertension treatment and diagnosis status, smoking, and body mass index for adults 30 to 70 years of age from nationally representative surveys in 50 low- and middle-income countries (N = 1 037 215). We aimed to determine the effect of hypertension guideline choice on the proportion of adults in need of blood pressure-lowering medications. We considered 4 hypertension guidelines the 2017 American College of Cardiology/American Heart Association guideline, the commonly used 140/90 mm Hg threshold, the 2016 World Health Organization HEARTS guideline, and the 2019 UK National Institute for Health and Care Excellence guideline.

RESULTS:

The proportion of adults in need of blood pressure-lowering medications was highest under the American College of Cardiology/American Heart Association, followed by the 140/90 mm Hg, National Institute for Health and Care Excellence, and World Health Organization guidelines (American College of Cardiology/American Heart Association women, 27.7% [95% CI, 27.2-28.2], men, 35.0% [95% CI, 34.4-35.7]; 140/90 mm Hg women, 26.1% [95% CI, 25.5-26.6], men, 31.2% [95% CI, 30.6-31.9]; National Institute for Health and Care Excellence women, 11.8% [95% CI, 11.4-12.1], men, 15.7% [95% CI, 15.3-16.2]; World Health Organization women, 9.2% [95% CI, 8.9-9.5], men, 11.0% [95% CI, 10.6-11.4]). Individuals who were unaware that they have hypertension were the primary contributor to differences in the proportion needing treatment under different guideline criteria. Differences in the proportion needing blood pressure-lowering medications were largest in the oldest (65-69 years) age group (American College of Cardiology/American Heart Association women, 60.2% [95% CI, 58.8-61.6], men, 70.1% [95% CI, 68.8-71.3]; World Health Organization women, 20.1% [95% CI, 18.8-21.3], men, 24.1.0% [95% CI, 22.3-25.9]). For both women and men and across all guidelines, countries in the European and Eastern Mediterranean regions had the highest proportion of adults in need of blood pressure-lowering medicines, whereas the South and Central Americas had the lowest.

CONCLUSIONS:

There was substantial variation in the proportion of adults in need of blood pressure-lowering medications depending on which hypertension guideline was used. Given the great implications of this choice for health system capacity, policy makers will need to carefully consider which guideline they should adopt when scaling up hypertension care in their country.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Presión Sanguínea / Hipertensión / Antihipertensivos Tipo de estudio: Etiology_studies / Guideline / Observational_studies / Prevalence_studies / Qualitative_research / Risk_factors_studies / Systematic_reviews Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Circulation Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Presión Sanguínea / Hipertensión / Antihipertensivos Tipo de estudio: Etiology_studies / Guideline / Observational_studies / Prevalence_studies / Qualitative_research / Risk_factors_studies / Systematic_reviews Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Circulation Año: 2021 Tipo del documento: Article